Qualit-E-SpeakPharma-Insert
X

Find Gastroenterology Clinical Drug Pipeline Developments & Deals

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bismuth Subsalicylate

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Arcadia Consumer Healthcare

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 20, 2020

            Details:

            Acquisition further strengthens Arcadia's consumer healthcare product portfolio.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cobitolimod

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Vinnova

            Deal Size: $0.1 million Upfront Cash: Undisclosed

            Deal Type: Funding March 31, 2020

            Details:

            The grant will be used for a preclinical project to evaluate selected compounds from InDex's DIMS platform in inflammatory disease models outside the field of inflammatory bowel disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORP-101

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2020

            Details:

            OrphoMed has paused new patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D) in response to the COVID-19 pandemic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antolimab

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2020

            Details:

            Six-month treatment with antolimab resulted in a 64 percent mean reduction in TSS-8 compared to baseline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cellspan Esophageal Implant

            Therapeutic Area: Gastroenterology

            Highest Development Status: IND Enabling Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 20, 2020

            Details:

            The FDA notified the Company that it removed the clinical hold and that the Company may proceed with its study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Eravacycline

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: AcelRx Pharmaceuticals

            Deal Size: $26.9 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 16, 2020

            Details:

            Tetraphase and AcelRx entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain.

            Massachusetts General Hospital

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vedolizumab

            Therapeutic Area: Gastroenterology

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Royalty Pharma

            Deal Size: $94.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 05, 2020

            Details:

            Through transactions such as this, Royalty Pharma is furthering our goal of accelerating innovation and making the life sciences research and development ecosystem more efficient and productive.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Brilacidin

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 05, 2020

            Details:

            The Company is presently interviewing Contract Research Organizations for site selection with the understanding that the goal is to initiate the trial this summer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Linaprazan

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fourth Swedish National Pension Fund

            Deal Size: $25.6 million Upfront Cash: Undisclosed

            Deal Type: Financing March 04, 2020

            Details:

            The proceeds from the financing round will be used to perform a phase 2 clinical trial, which is expected to start in the second half of 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vedolizumab

            Therapeutic Area: Gastroenterology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 28, 2020

            Details:

            If approved, vedolizumab will become the only maintenance therapy for ulcerative colitis or Crohn's disease with both intravenous and subcutaneous formulations across the European Union.

            PharmaCompass